Read more at MarketWatch.
Philips shares climb after finalizing pact with U.S. over device sales
Date: |
Sort by
Filter
Date
Items per page
-
Philips shares surge after $1.1bn settlement over sleep apnoea devices
Cost of settling litigation in US over faulty machines is less than what market had expectedFinancial Times - Business -
Philips shares surge after $1.1bn settlement over sleep apnoea devices
Cost of settling litigation in US over faulty machines is less than what market had expectedFinancial Times - Business -
Philips shares rocket 29% as firm settles U.S. respiratory device case
Philips shares soared Monday after the company agreed to a $1.1 billion settlement in a U.S. case linked to the recall of some of its sleep apnea devices.CNBC - Business -
Philips shares rocket 29% as firm settles U.S. respiratory device case
Philips shares soared Monday after the company agreed to a $1.1 billion settlement in a U.S. case linked to the recall of some of its sleep apnea devices.CNBC - Business -
Philips shares rocket 29% as firm settles U.S. respiratory device case
Philips shares soared Monday after the company agreed to a $1.1 billion settlement in a U.S. case linked to the recall of some of its sleep apnea devices.CNBC - Business -
Philips shares soar 30% after U.S. litigation settlement far lower than feared
The company said it would pay $1.1 billion to resolve personal injury and medical monitoring litigation in the U.S. Worst-case expectations among analysts called for up to $10 billion.MarketWatch - Business -
Philips Settles U.S. Ventilator Claims
Philips has reached a $1 billion settlement in the U.S. related its Respironics ventilators, and backed its full-year guidance.The Wall Street Journal - World -
Philips Settles U.S. Ventilator Claims
Philips has reached a $1 billion settlement in the U.S. related its Respironics ventilators, and backed its full-year guidance.The Wall Street Journal - Business -
Acrivon Therapeutics’ shares climb 14% on plans to present cancer-test data
Shares of Acrivon Therapeutics advanced in post-market trading after the biopharmaceutical company said it would present clinical trial data in connection with a biomarker test for ovarian and endometrial cancers.MarketWatch - Business -
Thoma Bravo to buy UK-listed Darktrace for £4.3bn
Offer comes less than two years after private equity group held talks about buying cyber security companyFinancial Times - Business
More from MarketWatch
-
The battle between athleisure and wider-leg pants is here. That means more trouble for Lululemon, analyst says.
After the skinny jean’s nearly two-decade reign, retailers and clothing makers say looser fits are getting more popular.MarketWatch - Business -
Long-term yields fall for second session as investors focus on Fed, jobs data and Treasury announcements
Rates on U.S. government debt finished slightly lower on Monday as traders looked ahead to the Federal Reserve’s policy decision and April’s official jobs report later this week.MarketWatch - Business -
Oil ends lower on Israel-Hamas cease-fire talks, Canada’s Trans Mountain pipeline expansion
Oil futures declined on Monday, with U.S. prices settling at their lowest in about a month, as efforts to broker a cease-fire between Israel and Hamas helped to ease concerns over potential supply disruptions in the region.MarketWatch - Business - Israel -
Boeing scores $10 billion bond financing in ‘much-needed’ liquidity boost
Fresh off reporting a more than $300 million quarterly loss, Boeing Co. saw robust demand on Monday for its $10 billion corporate-bond deal.MarketWatch - Business -
AMC’s stock on pace for biggest decline in a month after preliminary first-quarter results
Shares of AMC Entertainment Holdings Inc. are down 11.6% Monday, putting the stock on pace for its biggest decline since April 1, when it fell 15.6%.MarketWatch - Business